

Claims

What is claimed is:

1. Use of a compound of Formula (I) or a pharmaceutically acceptable salt, solvate or prodrug in the manufacture of a medicament for prevention and/or treatment of a disease or disorder mediated by NLRP3,




(I)



(I)

wherein n is 0 or 1,

X is –S–, –S(=O)– or –NR_n–; wherein

R_n is H or 

;

A is –CH, –CR_c or N;

R_a is –C(=O)OR_{a1}, –OR_{a2}, –O–C(=O)R_{a3} or –O–C(=O)-T-OR_{a4}; wherein

R_{a1} is H or linear or branched $C_{1\text{-}15}$alkyl;

R_{a2} is H, linear or branched $C_{1\text{-}15}$alkyl, phosphonate, diarylphosphonate or an *O*-protecting group;

R_{a3} and R_{a4} are independently a protecting group, linear or branched C_{1-15}alkyl, linear or branched C_{2-15}alkenyl, -T-C_{3-10}cycloalkyl, -T-NHR_{a3p}, -T-C_{3-10}cycloalkenyl, -T-C_{6-10}aryl, -T-C_{5-10}heteroaryl, -T-NH-C(=O)-O-C_{1-10}alkyl, -T-adamantyl or -C_{1-3}alkylene-C_{6-10}aryl where the alkylene is substituted with -T-NHR_{a3p};

R_{a3p} is H or an *N*-protecting group;

R_b is H, linear or branched C_{1-15}alkyl, linear or branched C_{2-15}alkenyl, C_{1-3}alkoxy-C_{1-15}alkyl-, -T'-C_{3-10}cycloalkyl, -T'-C_{3-10}cycloalkenyl, -T'-C_{6-10} aryl or -T'-C_{5-10}heteroaryl;

R_c each is independently halogen, linear or branched C_{1-15}alkyl, linear or branched C_{1-15}alkoxyl, unprotected or protected hydroxyl group, or –C_{1-10}alkylene-Y-C_{6-10}heteroaryl wherein -Y- is -CH_2-, -NH-, -O- or -S-;

symbol * represents the bonding position;

m is an integer from 0 to 4;

-T- is absent, C_{1-3}alkylene or C_{2-3}alkenylene;

-T'- is C_{1-3}alkylene or C_{2-3}alkenylene; and

wherein the heteroaryl contains at least one heteroatom, each heteroatom being independently S, N or O;

wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heteroaryl, alkylene and alkenylene are each independently unsubstituted or substituted with at least one substituent;

wherein the substituent is each independently a halogen, a protecting group, protected or unprotected amino group, nitro, nitroso, linear or branched C_{1-15} alkyl,or linear or branched C_{1-15} alkoxy or C_{3-10}cycloalkyl; and

when R_b is H, the tautomers are included,

with the proviso that

when X is –S– or –S(=O)–, R_a is –OR_{a2} and R_{a2} is H or linear or branched C_{1-15}alkyl, then A is –CH or –CR_c;

when X is –S– or –S(=O)– and R_a is –C(=O)OR_{a1}, R_b is linear or branched C_{6-15}alkyl, linear or branched C_{6-15}alkenyl, C_{1-3}alkoxy-C_{1-15}alkyl-, -T'-C_{3-10}cycloalkyl, -T'-C_{3-10}cycloalkenyl, -T'-C_{6-10} aryl or -T'-C_{5-10}heteroaryl;

or a pharmaceutically acceptable salt thereof.

2. The use of Claim 1, wherein the disease or disorder is selected from inflammasome-related diseases or disorders, immune diseases, inflammatory diseases, auto-immune diseases, or auto-inflammatory diseases, liver related diseases or disorders, inflammatory arthritis related disorders, kidney related diseases, neuroinflammation-related diseases, cardiovascular or metabolic diseases or disorders, inflammatory skin diseases, wound healing and scar formation, asthma, sarcoidosis, age- related macular degeneration, or cancer related diseases or disorders.

3. The use of Claim 2, wherein the disease or disorder is selected from autoinflammatory fever syndromes, chronic liver disease, viral hepatitis, non alcoholic steatohepatitis (NASH), alcoholic steatohepatitis, alcoholic liver disease, gout, pseudogout (chondrocalcinosis),

osteoarthritis, rheumatoid arthritis, arthropathy, hyperoxaluria, lupus nephritis, hypertensive nephropathy, hemodialysis related inflammation, multiple sclerosis, brain infection, acute injury, neurodegenerative diseases, Alzheimer's disease (AD), cardiovascular risk reduction (CvRR), hypertension, atherosclerosis, type I and type II diabetes and related complications, peripheral artery disease (PAD), acute heart failure, hidradenitis suppurativa, acne, colon cancer, lung cancer, myeloproliferative neoplasms, leukemias, myelodysplastic syndromes (MDS), myelofibrosis, multiple system atrophy (MSA), or dementia with Lewy bodies.

4. The use of Claim 3, wherein the disease or disorder is selected from cryopyrin-associated periodic syndrome, nephropathy, or retinopathy.

5. The use of Claim 1, wherein the disease or disorder is selected from a neurological disorder, symptom domains of schizophrenia and schizoaffective disorder, depression, Tourette Syndrome, Post-traumatic stress disorder (PTSD), Obsessive-compulsive disorder (OCD), analgesics, loss of memory and/or cognition associated with neurodegenerative diseases or loss of neuronal function characteristic of neurodegenerative diseases, mild cognitive impairment (MCI), Alzheimer's disease, Parkinson's disease (PD), schizophrenia, pain, ataxia, convulsion, anxiety, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), fragile X syndrome (FXS), autism, or attention-deficit/hyperactivity disorder (ADHD).

6. The use of Claim 1, wherein n is 0.

7. The use of Claim 1, wherein m is an integer from 0 to 3.

8. The use of Claim 1, wherein:

n is 0;

X is —S(═O);

A is N;

R_a is –O–C(=O)R_{a3} or –O–C(=O)-T-OR_{a4}; wherein

R_{a3} is a linear or branched $C_{1\text{-}15}$alkyl, linear or branched $C_{2\text{-}15}$alkenyl, -T-$C_{3\text{-}10}$cycloalkyl, -T-NHR_{a3p}, -T-$C_{3\text{-}10}$cycloalkenyl, -T-$C_{6\text{-}10}$aryl, -T-$C_{5\text{-}10}$heteroaryl, -T-NH-C(=O)-O-$C_{1\text{-}10}$alkyl, -T-adamantyl or -$C_{1\text{-}3}$alkylene-$C_{6\text{-}10}$aryl where the alkylene is substituted with -T-NHR_{a3p};

R_{a4} is a linear or branched C_{1-15}alkyl, linear or branched C_{2-15}alkenyl, -T-C_{3-10}cycloalkyl, -T-NHR_{a3p}, -T-C_{3-10}cycloalkenyl, -T-C_{6-10}aryl, -T-C_{5-10}heteroaryl, -T-NH-C(=O)-O-C_{1-10}alkyl, -T-adamantyl or -C_{1-3}alkylene-C_{6-10}aryl where the alkylene is substituted with -T-NHR_{a3p};

R_{a3p} is H or an *N*-protecting group selected from Fmoc or Boc;

or a pharmaceutically acceptable salt thereof.

9. The use of Claim 8, wherein:

A is N;

R_b is H;

m is 3; and

R_c each is independently linear or branched C_{1-15}alkyl, linear or branched C_{1-15}alkoxyl; or a pharmaceutically acceptable salt.

10. The use of Claim 8, wherein R_a is –O–C(=O)R_{a3} wherein R_{a3} is adamantyl; linear or branched C_{1-10}alkyl unsubstituted or substituted by halogen; C_{1-4}alkoxy; -C_{6-10}aryl unsubstituted or substituted by C_{1-10} alkyl, nitro, C_{1-15}alkoxy or halogen; C_{3-10}cycloalkyl; -C_{3-10}cycloalkenyl; linear or branched C_{2-10}alkenyl; -C_{5-10}heteroaryl; -C_{1-3}alkylene-C_{3-10}cycloalkyl; C_{2-3}alkenylene-C_{6-10}aryl wherein C_{6-10}aryl is unsubstituted or substituted by halogen; –O–C(=O)-O-C_{1-10}alkyl.

11. The use of Claim 8, wherein R_a is –O–C(=O)R_{a3} wherein R_{a3} is adamantyl; linear or branched C_{1-8}alkyl unsubstituted or substituted by halogen; C_{1-4}alkoxy; -phenyl unsubstituted or substituted by C_{1-6} alkyl, nitro, C_{1-4}alkoxy or halogen; C_{3-6}cycloalkyl; -C_{3-6}cycloalkenyl; linear or branched C_{2-6}alkenyl; -C_{5-6}heteroaryl; -C_{1-3}alkylene-C_{3-6}cycloalkyl; C_{2-3}alkenylene-phenyl wherein phenyl is unsubstituted or substituted by halogen; –O–C(=O)-O-C_{1-4}alkyl.

12. The use of Claim 8, wherein R_a is –O–C(=O)-C_{1-6}alkyl, –O–C(=O)-C_{1-3}alkylene-NHFmoc,–O–C(=O)-C_{1-3}alkylene-NHBoc or –O–C(=O)-NH-C(=O)-O-C_{1-10}alkyl.

13. The use of Claim 8, wherein R_c each is independently halogen, linear or branched C_{1-6}alkyl, linear or branched C_{1-6}alkoxyl, or –C_{1-10}alkenylene-Y-C_{6-10}heteroaryl; wherein Y is S and

C_{6-10}heteroaryl is unsubstituted or substituted by C_{1-15}alkyl, C_{1-15}alkoxy, -OH, $-NH_2$, $-NO_2$ or halogen.

14. The use of Claim 1, wherein:

X is –S–;

A is N;

R_a is $–C(=O)OR_{a1}$; wherein R_{a1} is H or linear or branched C_{1-15}alkyl;

or a pharmaceutically acceptable salt thereof.

15. The use of Claim 14, wherein R_a is $–C(=O)OH$, or $–C(=O)OC_{1-4}$alkyl.

16. The use of Claim 1, wherein the compound is selected from the group consisting of:

RS-D7: 5-O-Desmethyl-Omeprazole

Esomeprazole: (S)-(−)-5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-3H-benzoimidazole

21122: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl acetate)

21124: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl benzoate)

26096: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl butyrate)

26097: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl cyclohexanecarboxylate)

26098: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 4-butylbenzoate)

21127: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 3-methylbenzoate)

27076: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl hexanoate

27077: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl isobutyrate

27078: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl cyclohex-3-ene-1-carboxylate)

27079: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl cyclohex-3-enecarboxylate

28087: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 4-methylbenzoate)

28091: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 2-nitrobenzoate)

28092: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl cyclopropanecarboxylate)

28093: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 2-ethylbutanoate)

28094: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 2-phenylacetate)

28095: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 3,5,5-trimethylhexanoate

28096: (2-(((5-methoxy-4,6-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 2-ethoxybenzoate)

21123: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl propionate)

21125: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 4-chlorobenzoate)

21126: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 3-nitrobenzoate)

21128: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl heptanoate

21129: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 4-fluorobenzoate)

21130: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl (Z)-2-methylbut-2-enoate)

21131: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 2-chloropropanoate)

21132: tert-butyl (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl) carbonate

12124: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl (Z)-but-2-enoate)

12125: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 3-methylbut-2-enoate)

12122: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl furan-2-carboxylate)

12123: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl acrylate)

12127: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 2-methylbutanoate)

12128: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 3-cyclopentylpropanoate)

12129: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl (E)-3-(2-chlorophenyl)acrylate)

12130: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 6-bromohexanoate)

11021: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 2-fluorobenzoate)

11020: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 4-methoxybenzoate)

11022: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl (3r,5r,7r)-adamantane-1-carboxylate)

11023: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl isoxazole-5-carboxylate)

11030: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 4-(tert-butyl)benzoate)

11031: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 3-chloro-4-fluorobenzoate)

25015: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl pivalate)

25016: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl pentanoate)

25017: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 4-nitrobenzoate)

25027: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl cyclobutanecarboxylate)

25028: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl thiophene-2-carboxylate)

25029: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 2-methylbutanoate)

25030: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 3,3-dimethylbutanoate)

25031: (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl 2-methoxyacetate)

25032: (ethyl (2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl) carbonate)

12082: Methyl 1-(2-(cyclohex-1-en-1-yl)ethyl)-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole-5-carboxylate

12083: 1-(2-(cyclohex-1-en-1-yl)ethyl)-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole-5-carboxylic acid

12084: Methyl 1-(2-(cyclohex-1-en-1-yl)ethyl)-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole-5-carboxylate

12088: methyl 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)thio)-1-octyl-1H-benzo[d]imidazole-5-carboxylate

21098: Methyl 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)- 1-propyl-1H-benzo[d]imidazole-5-carboxylate

26065: Methyl 1-(furan-2-ylmethyl)-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1H-benzo[d]imidazole-5-carboxylate

21102: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1-propyl- 1H-benzo[d]imidazole-5-carboxylic acid

21103: Methyl 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1- (3-methoxypropyl)-1H-benzo[d]imidazole-5-carboxylate

21104: 2-(bis((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1- (3-methoxypropyl)-1H-benzo[d]imidazole-5-carboxylic acid

26066: Methyl 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1-pentyl-1H-benzo[d]imidazole-5-carboxylate

21105: 2-(bis((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1- (2-(cyclohex-1-en-1-yl)ethyl)-1H-benzo[d]imidazole-5-carboxylic acid

26070: 1-(furan-2-ylmethyl)-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

26071: Methyl 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1-(4-methoxybenzyl)-1H-benzo[d]imidazole-5-carboxylate

26072: Methyl 2-(bis((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-3-(furan-2-ylmethyl)-3,4-dihydroquinazoline-7-carboxylate

21106: Methyl 3-(2-(cyclohex-1-en-1-yl)ethyl)-2-(((4-methoxy-3,5- dimethylpyridin-2-yl)methyl)amino)-3,4-dihydroquinazoline-7-carboxylate

12092: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)thio)-1H-benzo[d]imidazol-5-yl (((9H-fluoren-9-yl)methoxy)carbonyl)glycinate

12093: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)thio)-1H-benzo[d]imidazol-5-yl (tert-butoxycarbonyl)glycinate

21110: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-3- (3-methoxypropyl)-3,4-dihydroquinazoline-7-carboxylic acid

26076: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1-pentyl-1H-benzo[d]imidazole-5-carboxylic acid

26077: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1-(4-methoxybenzyl)-1H-benzo[d]imidazole-5-carboxylic acid

12094: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)thio)-1H benzo[d]-imidazole-5-yl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-phenylacetate

13001: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-6-yl 2-((tert-butoxycarbonyl)amino)acetate

13084: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-yl diphenyl phosphate

26079: Methyl 3-(furan-2-ylmethyl)-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-3,4-dihydroquinazoline-7-carboxylate

26089: 3-(furan-2-ylmethyl)-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-3,4-dihydroquinazoline-7-carboxylic acid

26090: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-3-pentyl-3,4-dihydroquinazoline-7-carboxylic acid

26091: Methyl 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-3-pentyl-3,4-dihydroquinazoline-7-carboxylate

26092: Methyl 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-3-(4-methoxybenzyl)-3,4-dihydroquinazoline-7-carboxylate

21115: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1- (3-methoxypropyl)-1H-benzo[d]imidazole-5-carboxylic acid

21116: Methyl 1-(2-(cyclohex-1-en-1-yl)ethyl)-2-(((4-methoxy-3,5- dimethylpyridin-2-yl)methyl)amino)-1H-benzo[d]imidazole-5-carboxylate

21117: 1-(2-(cyclohex-1-en-1-yl)ethyl)-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

21118: Methyl 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1- phenethyl-1H-benzo[d]imidazole-5-carboxylate

21119: 2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1-phenethyl- 1H-benzo[d]imidazole-5-carboxylic acid

21120: 2-(bis((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1-propyl- 1H-benzo[d]imidazole-5-carboxylic acid

21121: 2-(bis((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)amino)-1-phenethyl- 1H-benzo[d]imidazole-5-carboxylic acid

22138: 5-methoxy-2-((2-methoxy-3,6-dimethylbenzyl)thio)-1H-benzo[d]imidazole

22139: 5-methoxy-2-((2-methoxy-3,6-dimethylbenzyl)sulfinyl)-1H-benzo[d]imidazole

22140: 2,2'-(((2-methoxy-4-methyl-1,3-phenylene)bis(methylene))bis(sulfanediyl))bis(5-methoxy-1H-benzo[d]imidazole)

21133: 2-((3-(bromomethyl)-2-((tert-butyldimethylsilyl)oxy)-6-methylbenzyl)thio)-5-methoxy-1H-benzo[d]imidazole and

22141: 2-((2-methoxy-3,6-dimethylbenzyl)thio)-1H-benzo[d]imidazol-5-ol

or a pharmaceutically acceptable salt thereof.

17. The use of Claim 15, wherein R_c each is independently halogen, linear or branched C_{1-6}alkyl, linear or branched C_{1-6}alkoxyl, or $–C_{1-10}$alkenylene-Y-C_{6-10}heteroaryl; wherein Y is S and C_{6-10}heteroaryl is unsubstituted or substituted by C_{1-15}alkyl, C_{2-15}alkenyl, C_{1-15}alkoxy, -OH, $-NH_2$, $-NO_2$ or halogen.